T he most biologically potent, endogenous estrogen, 17␤-estradiol (E2), is able to enhance vascular NO bioavailability by chronically increasing endothelial NO synthase (eNOS) expression and acutely stimulating eNOS activity through estrogen receptor (ER)-dependent signal transduction, most notably involving the phosphatidylinositol 3-kinase/Akt/eNOS pathway in endothelial cells (EC). This notion serves as one fundamental explanation for E2-induced vascular protection against ischemia/reperfusion injury, atherosclerosis progression, and neointima formation. Although membrane ER␣ and membrane ER46 (a de novo truncated ER␣) are now appreciated to initiate estrogen-stimulated, c-Srcdependent eNOS activation after acquiring c-Src activity (1) (2) (3) , little is known about the molecular details of c-Src involvement and the importance of c-Src in estrogen-induced vasorelaxation.
In mammals, Src family kinases have at least eight structurally distinct members and pivotally regulate cell migration, adhesion, proliferation, differentiation, and survival (4) . Among eight Src kinase family members, only c-Src, Fyn, and Yes are ubiquitously expressed. Phosphorylation of c-Src Y416 with concomitant Y527 dephosphorylation is a consequence of c-Src activation and often leads to full kinase activity (4) . c-Src family members are location-sensitive, membrane-associated, nonreceptor tyrosine kinases. c-Src kinase is reversibly coupled to the inner leaflet of the plasma membrane via a myristate moiety covalently attached to the G2 residue and a polybasic cluster embedded in the N terminus (5) . All Src tyrosine kinases have a characteristic structure including single Src homology (SH) 3, SH2, and protein tyrosine kinase domains. Cytosolic c-Src is often self-restrained to an inactive conformation by both intramolecular and intermolecular interactions between its SH2 domain and phospho-Y527 and between its SH3 domain and SH2-kinase linker domains. Disrupting the inhibitory conformation by Y527 dephosphorylation or protein binding to the SH2 or SH3 domains imparts c-Src with an open structure permissive for Y416 autophosphorylation and resultant kinase activation (6, 7) .
c-Src kinase can phosphorylate ER␣ at Y537 in resting cells, and, in turn, the c-Src SH2 domain can directly bind to ER␣ phospho-Y537 (8, 9) . The ''open'' conformation, normally prompted via Y527 dephosphorylation by protein tyrosine phosphatase (PTP) ␣, PTP␥, PTP1B, or SHP-2 (6, 7), governs molecular recognition of c-Src substrates and its binding partners and is necessary for the redistribution of c-Src from endosomes to focal adhesions (10) . In this article we present the molecular dissection of c-Src membrane-ER46 interactions, including interdependence for membrane targeting. We also display, by use of aortas obtained from c-Src gene-deleted animals, the critical role of c-Src in estrogen-induced vascular responses.
Results

c-Src Requirement in
Basal and E2-Induced Vasorelaxation. To determine whether c-Src plays a physiological role in E2-induced vasomotor responses, we analyzed the basal and E2-modulated vascular tone ex vivo by myography. E2 (10 Ϫ6 to 3 ϫ 10 Ϫ5 M) induced 10 -65% vasorelaxation of L-phenylephrine (PE)-preconstricted control aortic rings and 4-22% in c-Src Ϫ/Ϫ aortic rings (representative myographs shown in Fig. 1A ). That is, E2-induced vasodilation was markedly blunted in aortic rings from c-Src gene-deleted mice. The observed relaxation was partially suppressed by N-nitro-L-arginine methyl ester hydrochloride (L-NAME) (38 Ϯ 2.6%, E2 ϭ 3 ϫ 10 Ϫ5 M, n ϭ 6, P Ͻ 0.05) and ICI 182,780 (66 Ϯ 3.2%, E2 ϭ 10 Ϫ5 M, n ϭ 5, P Ͻ 0.05), indicating that E2-enhanced NO bioavailability, through ER signaling, is at least partially responsible for the observed vasodilation (Fig. 1B) . Endothelial denudation abolished E2-induced vasorelaxation in c-Src ϩ/ϩ and c-Src Ϫ/Ϫ aortic rings, and sodium nitroprusside (NO donor, 10 Ϫ6 M) produced comparable vasodilating responses in both [see supporting information (SI) Fig. 7 ]. These results suggest that the differential response to E2 (Fig. 1 A) was due largely to the difference in endotheliumderived vasodilator production and that smooth muscle responses were identical. In intact, non-denuded rings, acetylcholine (10 Ϫ6 M) responses were also similar (see SI Fig. 7 ). This indicates not only that the endothelium is intact and eNOS responses are preserved in c-Src Ϫ/Ϫ mice, but also that there is some specificity to the molecular complex that transduces estrogen-triggered signals. E2 stimulation of aortic rings was also performed in the presence of prostaglandin synthesis inhibition (indomethacin). Although the resting tone was greater in the presence of indomethacin, the vasodilating response to E2 was unaffected (data not shown). L-NAME pretreatment followed by PE challenge was also used to evaluate basal NO release. PE-induced, basal aortic tone in c-Src Ϫ/Ϫ rings was equal to that observed in L-NAME-treated wild-type rings (data not shown). These data implicate c-Src as a physiologically relevant modulator for basal and E2-induced vasorelaxation in murine aortas.
E2-Induced c-Src Phosphorylation Status and c-Src Requirement in
eNOS Activation. To document a c-Src requirement in E2-induced eNOS activation, we compared responsiveness in murine embryonic fibroblasts derived from embryos lacking all three major Src kinase members, Yes, Fyn, and c-Src (SYF Ϫ/Ϫ ), to those observed in the same cells with c-Src reconstitution by stable c-Src expression (YF Ϫ/Ϫ ). In triple knockout SYF Ϫ/Ϫ murine embryonic fibroblasts that heterologously express human ER46 and bovine eNOS, E2 failed to activate eNOS. However, E2 stimulation did increase eNOS activity (2.7 Ϯ 0.4-fold) in YF Ϫ/Ϫ , Src ϩ/ϩ cells ( Fig. 2A) . Expressed ER46 and eNOS levels in these transfected cells were equal (SI Fig. 8 ). Phosphorylation of c-Src Y419 (avian Y416) with concomitant Y530 (avian Y527) dephosphorylation is a consequence of c-Src activation and often leads to full kinase activity (4) . In human umbilical vein ECs that contain both full-length ER␣ (referred to as ER␣, unless otherwise indicated) and ER46, and EA.hy926 cells (an immortalized human umbilical vein EC line) that conditionally express ER46 only (2), E2 stimulated phosphorylation of c-Src on Y419 residue in 5-15 min while the levels of phospho-Y530 and non-phospho-Y530 remained unchanged (Fig. 2B ). This is in contrast to PDGF-induced, parallel EC c-Src phosphorylation and dephosphorylation. Thus, the E2-induced eNOS activation
E2, L-NAME (n = 3) requires the presence of c-Src, which becomes phosphorylated on Y419 in the absence of c-Src Y530 dephosphorylation.
ER46 -c-Src
Interdependence for Plasma Membrane Localization. Several features of ER, c-Src, and eNOS membrane targeting have been described (3, 11, 12) , but molecular interdependence of such has not been addressed. c-Src was coimmunoprecipitated with ER46 and eNOS from EA.hy926 plasma membranes but not from the cytosol. E2 or membrane-impermeant E2BSA enhanced the association of ER46, c-Src, and eNOS in the membrane (Fig. 3A) . Decrease of ER46 expression (65%) with antisense ER␣ in EA.hy926 cells (Fig. 3C ) or overexpression of myristoylationdeficient c-Src mutants in ER46-transfected COS-7 cells diminished the plasma membrane appearance of c-Src and ER46 ( Fig. 3  B and C) . The levels of eNOS in plasma membranes (Fig. 3C ) and of total Hsp90 (Fig. 3B ) in cell lysates were not altered by AsER␣ and SrcG2A expression, indicating the specificity of changes in targeted genes. Of note, expression of exogenous avian c-Src (aSrc) in COS-7 cells reduced the levels of endogenous c-Src. This may explain why heterologous c-Src expression apparently masked the role of endogenous c-Src in these studies (Figs. 3 and 4) . These results indicate that, in addition to palmitoylation and myristoylation, known to be important for membrane localization of ER46 (2) and c-Src (5), respectively, ER46 and c-Src are interdependent for membrane incorporation, possibly because of their proteinprotein interaction.
ER46 -c-Src Interaction Domains.
To define ER46 and c-Src domains that confer the aforementioned, critical interactions, a series of avian (to distinguish between endogenous and transfected) c-Src mutants were cotransfected with ER46 (and, in activation experiments, with eNOS) into COS-7 cells, followed by coimmunoprecipitations. Before doing so, metabolic labeling experiments were performed to determine whether E2 induces a c-Src-dependent phosphorylation of ER46 in EC. In EA.hy926 cell ER46-Src-eNOS immunocomplexes (Fig. 3D ), E2 stimulates ER46 phosphorylation in vitro, a process blocked by both the Src inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4-d] pyrimidine (PP2) (95%) and the pure ER antagonist ICI 182,780 (70%). Because Y537 is the only known c-Src substrate residue in ER␣ (9, 13), it is likely that this phosphorylation event enhances, or is even responsible for, the ER46-cSrc interaction in EC. This is supported by our finding that, after E2 stimulation, ER46 antibody coimmunoprecipitated wild-type aSrc and the SH3 mutant aSrcW118L, but not the SH2 mutant aSrcR175L (Fig. 4) , one shown to abrogate c-Src interactions with phosphotyrosine-containing proteins (14) . As noted above, c-Src is often self-restrained to an inactive conformation by both intramolecular and intermolecular interactions between its SH2 domain and phospho-Y530 and between its SH3 domain and SH2-kinase linker domains. To determine whether the c-Src substrate-accessible open structure and/or kinase activation are required for c-Src localization in membrane ER46 complexes, the avian c-Src constructs including wild-type Src, SrcY527F (open and active), SrcK295M (kinase-dead), and SrcY527F/ K295M (substrate-accessible but kinase-dead) were separately expressed in ER46-reconstituted COS-7 cells (Fig. 5A ). Wildtype Src expression supported E2BSA-stimulated membrane ER46 recruitment. Conversely, SrcK295M, a kinase-dead mutant that is likely to adapt an inactive conformation, radically abolished (95%) membrane localization of ER46 in the presence and absence of E2BSA challenge. Both SrcY527F and SrcY527F/K295M elevated the basal level of membrane ER46. In these two transfectants, E2BSA-induced ER46 recruitment was not observed, likely because membrane ER46 levels were already near maximal. Furthermore, the changes of membrane ER46 expression conferred by wild-type Src or Src mutants correlate with the ability of ER46 to bind membraneimpermeant ligands, determined by HRP activity associated with membrane ER46 after E2HRP (membrane-impermeant) treatment of reconstituted COS-7 (Fig. 5B) , SYF Ϫ/Ϫ (Fig. 5C) , and YF Ϫ/Ϫ , Src ϩ/ϩ (Fig. 5D ) cells in culture. SrcY527F and SrcY527F/K295M increased (2.4 Ϯ 0.2-fold and 2.6 Ϯ 0.1-fold, 
Effect of ER46 -c-Src Interaction Domains on eNOS Activation.
We have demonstrated that c-Src tyrosine kinase activity is important for ligand-stimulated eNOS activation through ER46/phosphatidylinositol 3-kinase/Akt/eNOS signal transduction (3). We thus addressed how c-Src conformation determines c-Src kinase activity in this pathway. In ER46-and eNOS-reconstituted, selected Srctransfected COS-7 cells, E2 elicited a PP2-sensitive eNOS activity increase (1.6 Ϯ 0.3-fold) in wild-type Src transfectants (Fig. 6A) . In contrast, neither SrcK295M nor SrcY527F/K295M was able to confer E2-induced eNOS activation, further demonstrating that this pathway requires c-Src kinase activity. SrcY527F provided the cells with constitutively elevated eNOS activity that was neither enhanced nor inhibited by E2 and PP2, respectively. Similar findings were obtained if membrane-impermeant E2BSA was used in ER46-and eNOS-reconstituted SYF Ϫ/Ϫ and YF Ϫ/Ϫ , Src ϩ/ϩ cells (Fig. 6B) . The data strongly suggest that the open conformation, although permissive of ER46 interactions that are important for the multimeric complex assembly and membrane localization, cannot override the requirement for tyrosine kinase function and that c-Src kinase activity is mandatory for the E2-induced signaling event. The loss of sensitivity of SrcY527F to PP2 may be caused by unfolding the deep hydrophobic pocket, a tertiary structure essential to PP2 binding to the Src family lck tyrosine kinase (15) . Notably, in EA.hy926 cells, compared with heterologous expression of avian wild-type Src, avian SrcG2A mutants, defective in membrane ras activation (16) without affecting its tyrosine kinase activity (17) , were unable to transmit E2 or E2BSA signals for c-Src Y419 phosphorylation, eNOS S1177 phosphorylation, and eNOS activation ( Fig. 6 C and D) . Thus, membrane-initiated E2 signaling is directed through membrane-targeted c-Src.
Discussion
These studies focus on interactions between the ER␣ splice form, ER46, and the nonreceptor tyrosine kinase c-Src. We believe that their interdependence is critical for mutual membrane localization and transduction of E2-stimulated signals in EC. However, although important and, in fact, required in our system, these two proteins comprise a subset of signaling molecules within a membrane (caveolae)-localized complex that initiate rapid signaling responses to estrogen. Heterotrimeric G proteins including G␣i and G␤␥ have been shown to productively interact with ER␣ and promote E2-stimulated NO release (18, 19) . In some models, ER␣-dependent induction of eNOS can be driven by activation of matrix metalloproteinases, epidermal growth factor receptor activation, and consequent ERK MAP kinase activation cascades (20) . Additionally, rapid responses to nonpeptide hormones other than E2, triggering a phosphatidylinositol 3-kinase/Akt-dependent 
vehicle). (C and D)
Requirement of membrane c-Src kinase activity for eNOS activation in ECs. EA.hy926 cells electroporated with Src or SrcG2A were treated with 30 nM E2 or E2BSA for 10 min, fractionated, immunoblotted, and subjected to eNOS activity assay (n ϭ 3 in D). Lysate immunoblotting (C) was conducted on two different membranes that were transblotted with identical samples. eNOS activation, have been observed (21) . Thyroid hormone can trigger this rapid activation response through engagement of the predominant thyroid hormone receptor in EC, TR␣ 1 . Thus, there are clearly multiple potential rapid signaling pathways activated by ER engagement and redundancy of receptor classes that, upon engagement, can facilitate identical outcomes of endothelial activation, namely NO release.
Our studies indicate that c-Src is required for E2-induced vasorelaxation. Based on the inhibition of vasodilation observed when aortic rings were pretreated with L-NAME or a conventional ER antagonist, the induced vascular responses are, at least in part, NOand ER-dependent. These ex vivo data are entirely consistent with our (and others') prior in vitro findings that E2 triggers an ERdependent, c-Src/phosphatidylinositol 3-kinase/Akt-mediated activation of eNOS, with consequent EC NO release (2, 3, 12) . Recently, E2 has been shown to induce Akt S473 phosphorylation and rapid NO production in isolated cerebral blood vessels (22) , also consistent with both our ex vivo and in vitro data. In this work, in addition to demonstrating the vascular tissue correlate of our in vitro data, our efforts were directed at defining molecular interaction domains between ER and c-Src and assessing the importance of classical c-Src structure and function and the interdependence of these two molecules for plasma membrane targeting, all in the context of eNOS activation. Indeed, the molecular determinants of these activation events include an interdependent plasma membrane targeting with a subset of c-Src bearing a substrate-accessible conformation, as well as a function-modifiable Src kinase domain.
The c-Src C-terminal Y530 (avian 527) is an important regulatory phosphorylation site. Under basal conditions, 90-95% of the c-Src molecules are phosphorylated by constitutively active tyrosine kinases such as Csk and Chk (23) . The p-Y530 binds intramolecularly to its SH2 domain, generally believed to prevent substrate accessibility and the required Y419 (avian 416) phosphorylation. A key activation switch often occurs when phosphatases such as PTP␣ dephosphorylate p-Y530 with consequent dissociation from the SH2 binding pocket. In our study, c-Src presents a substrateaccessible conformation without Y530 dephosphorylation (Fig. 2) . Instead, protein-protein interactions, perhaps disrupting the intramolecular rigidity without affecting Y530 dephosphorylation (24, 25) , may largely contribute to opening c-Src. The availability of a low level of c-Src kinase activity in resting cells (13) and the increasing association of ER46 with E2 stimulation (Fig. 3A) may favor homotypic (26, 27) and heterotypic (24, 25) protein interactions with c-Src and further enforce c-Src ''opening.'' Indeed, it has been demonstrated that doubly phosphorylated c-Src can be active, such that Y419 phosphorylation can override the p-Y530-directed inhibition (28) . The balance of tyrosine kinase (Csk and Chk) and phosphatase (PTP␣) activity, in both basal and stimulated states, is partially responsible for the state of Src activation. We are currently investigating this balance in resting and E2-stimulated EC.
A number of posttranslational modifications and protein-protein interactions have been shown to direct ER localization to plasma membranes. These include palmitoylation on C447 (29) and caveolin-1 interaction with ER␣ S522 (30), the latter promoting targeting to specialized membrane rafts, caveolae, in EC. Furthermore, multiple proteins, including the modulator of nongenomic activity of ER (MNAR) and striatin, serve as scaffold molecules for membrane complexes containing ER with c-Src (31) and G␣i (32), respectively. Here we demonstrate that productive membrane targeting of c-Src (abrogated by the SrcG2A myristoylation mutant) is also important for maximal plasma membrane targeting of ER. We observed a rapid, E2-stimulated, Src-and ER-dependent ER46 phosphorylation. Although we do not map this phospho-site, others have demonstrated that ER␣ Y537, when inducibly phosphorylated, binds to the c-Src SH2 domain (31) . Because the SrcR175L SH2 mutant loses its E2-induced association with ER46 (Fig. 4) , it is likely that this Y537 is the critically stimulated phosphorylation/ activation site, responsible for triggering rapid signaling cascades, including those leading to eNOS activation and EC NO release.
We have used EC that, in our experimental conditions, express the truncated ER␣ splice form ER46 (2) . We have also used recombinant ER46 expression in heterologous systems to dissect these molecular interactions in vitro. We find that all of the membrane targeting, molecular complex assembly, and rapid activation responses are achievable with ER46 in EC. It is clear that full-length ER␣ can also localize to endothelial caveolar structures (31) , and the predominance of a given isoform in a physiologically or pathologically relevant vascular context is not known. Both full-length and truncated (Ϸ50 kDa) ERs have been coimmunoprecipitated with eNOS from rat cerebral vessels (22) . Also, the original ER␣ gene-deleted mouse (ER␣KO Chapel Hill), targeted for deletion within exon 1, was reexamined after vascular responses were found to be maintained. Indeed, truncation variants resulting from both splice and internal translation initiation sites within exon 2, ER55 and ER46, were demonstrated in the vasculature of that mouse and were capable of mediating estrogen responses (24, 33, 34) .
Our findings are consistent with human vascular endothelial expression of ER46, a receptor isoform that efficiently promotes the aforementioned, multimeric signalsome and, upon engagement by ligand, facilitates the signal transduction cascade, resulting in NO release (2, 3) . Given the major efforts directed at evaluating ovarian steroid replacement effects on the cardiovascular status of postmenopausal women, careful dissection of rapid, membrane-initiated, ER-dependent signaling is timely and critical to more carefully targeted future therapies.
Materials and Methods
Materials and Reagents. The anti-ER␣ antibody (F-10), all secondary antibodies, and protein A/G-plus reagent were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antibodies were used for c-Src (Ab-1; Oncogene Research Products, La Jolla, CA), avian Src (EC-10; Upstate Biotechnology, Lake Placid, NY), and eNOS (BD Transduction Laboratories, San Jose, CA), whereas rabbit polyclonal antibodies were used for phospho-S1177-eNOS, phospho-Y416-Src, phospho-Y527-Src, and nonphospho-Y527-Src from Cell SignalingTechnology (Beverly, MA). E2, water-soluble E2, PE hydrochloride, acetylcholine chloride, sodium nitroprusside, and L-NAME were purchased from Sigma (St. Louis, MO). LY294002 and PP2 were purchased from Calbiochem (La Jolla, CA), and ICI 182,780 was from Zeneca Pharmaceuticals (Wilmington, DE). All other reagents were purchased from Sigma unless otherwise noted. All cell culture media were purchased from GIBCO/BRL (Gaithersburg, MD).
Plasmids. ER46 (amino acids 174-595 of ER␣) was obtained by PCR amplification with primers containing a BamHI site using hER19Pu as a template. hER19Pu was gift from P. Chambon (Université Louis Pasteur, Strasbourg, France). The amplified fragment was then subcloned into pSG5 or pCMV-Tag3c (Stratagene). Insert for antisense ER␣ (AsER␣) construct was digested by BamHI from hER0Pu, containing human ER␣, and then subcloned into pCMV-Tag3c. The numbering of ER␣ refers to human ER␣ (Swiss-Prot accession no. P03372). The plasmids containing avian Src mutants such as SrcG2A, SrcW118K, and SrcR175L were prepared with the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) using avian Src/CA10 as a template. Avian Src constructs containing SrcY527F, SrcK295M, and SrcY527F/K295M were obtained from P. Schwartzberg (National Institutes of Health, Bethesda, MD) and J. Brugge (Harvard University, Cambridge, MA). The numbering of avian Src mutants and human Src refers to the sequences of chicken Src (Swiss-Prot accession no. P00523) and human Src (Swiss-Prot accession no. P12931), respectively. Constructs were all verified by sequencing.
